Landos Biopharma, Inc. (LABP) Financials

LABP Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 43.2 million 5.6 million
June 30, 2023 46.3 million 3.0 million
March 31, 2023 51.2 million 4.2 million
Dec. 31, 2022 45.3 million 6.1 million

LABP Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -2.2 million 248000
June 30, 2023 -5.1 million 254000
March 31, 2023 -8.2 million 224000
Dec. 31, 2022 -3.7 million 196000

LABP Net Income

No data available :(

LABP Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 42.5 million - -
June 30, 2023 44.7 million - -
March 31, 2023 50.0 million - -
Dec. 31, 2022 44.4 million - -

LABP Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 6.2 million
June 30, 2023 6.2 million
March 31, 2023 6.5 million
Dec. 31, 2022 4.0 million

LABP Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 - 3.1 million 2.1 million -
June 30, 2023 - 2.5 million 2.0 million -
March 31, 2023 - 3.3 million 3.2 million -
Dec. 31, 2022 7000 3.4 million 3.1 million -

LABP Cost of Revenue

No data available :(

LABP

Price: $22.93

52 week price:
2.50
22.93

Earnings Per Share: -3.50 USD

P/E Ratio: -1.37

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 125700

Market Capitalization: 69.4 million

Links: